If frataxin can do it so will ATH434 to the same.

Their conclusion: "Our study suggests that manipulating the expression of Fxn, a core component of Fe–S biogenesis machinery, may offer new therapeutic strategies for DPN. For instance, SS-31 or other untested drugs may improve the quality of life for DPN patients by rescuing or stabilizing Fe–S clusters. These findings provide significant scientific evidence for further exploration of therapeutic targets for DPN".

Think about the market of diabetic neuropathy, prevention, and treatment. This is only an animal study, but ATH434 is not in the next month.

Biochem Biophys Res Commun

. 2025 Jan:744:151228.

doi: 10.1016/j.bbrc.2024.151228. Epub 2024 Dec 20.

Low expression of Frataxin might contribute to diabetic peripheral neuropathy in a mouse model

Siyu Xia ¹, Lin Wu ², Jing Chen ¹, Kuanyu Li ³, Dezhi Bian ⁴

Affiliations Expand

• PMID: 39721363

DOI: 10.1016/j.bbrc.2024.151228Free article

Abstract

Diabetes is one of the most prevalent metabolic disorders, and its incidence has been experiencing a steady annual rise in recent years. Diabetic peripheral neuropathy (DPN) represents the most frequent adverse complication, exerting a profound impact on the quality of life for those suffering from diabetes. The etiology of DPN is complex, including impaired mitochondrial function. Iron-sulfur clusters (Fe-S) are essential cofactors for numerous essential enzymes crucial for mitochondrial function. Our previous study showed that expression of Frataxin, encoded by the Fxn gene, is downregulated in leptin receptor knockout (so-called db/db) mice, a commonly used DPN mouse model. Fxn is one of the core components of Fe-S biogenesis machinery. Here, we found that the mitochondria-targeted antioxidant SS-31 markedly improved the behavioral indices and significantly mitigated the damage to the sciatic nerve. SS-31 treatment effectively elevated Fxn expression, meliorated mitochondrial function, and inflammation in the sciatic nerve (SCN). We also found that SS-31 effectively mitigated high glucose-induced disruption of iron and redox homeostasis in RSC96 cells, a typical cell model of DPN, thereby improving mitochondrial function. These findings suggest enhancing Fe-S biogenesis could be an effective therapeutic strategy for treating DPN.